Upadacitinib Delivers Rapid Response in Ulcerative Colitis Upadacitinib Delivers Rapid Response in Ulcerative Colitis
Serious and severe adverse events, as well as higher rates of discontinuation due to treatment-related adverse events, were more common in the placebo group.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2021 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Consumer Health: Living with Crohn's disease and colitis
Crohn ’s and Colitis Awareness Week will be observed Dec. 1–7, which makes this a good time to learn about living with these disorders. Researchers estimate that more than half a million people in the U.S. have Crohn’s disease, and 600,000 to 900,000 people in the U.S. have ulcerative colitis, accor ding to the National Institute of Diabetes and Digestive and Kidney Diseases. Inflammatory bowel disease is an umbrella term used to describe disorders that involve chronic… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2021 Category: Databases & Libraries Source Type: news

What Is the Best Diet for Someone With Ulcerative Colitis?
Title: What Is the Best Diet for Someone With Ulcerative Colitis?Category: Diseases and ConditionsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 11/30/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 30, 2021 Category: Nutrition Source Type: news

When Do You Need Ulcerative Colitis Hospitalization?
Title: When Do You Need Ulcerative Colitis Hospitalization?Category: Diseases and ConditionsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 11/30/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 30, 2021 Category: Nutrition Source Type: news

Etrolizumab Down but Not Out for Ulcerative Colitis: Studies Etrolizumab Down but Not Out for Ulcerative Colitis: Studies
Etrolizumab does not appear to be effective as induction or maintenance therapy for moderately to severely active ulcerative colitis, according to results of five phase 3 trials.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 29, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

What Foods Trigger Ulcerative Colitis?
Title: What Foods Trigger Ulcerative Colitis?Category: Diseases and ConditionsCreated: 11/29/2021 12:00:00 AMLast Editorial Review: 11/29/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 29, 2021 Category: Nutrition Source Type: news

How Do I Know if My Ulcerative Colitis Is Flaring?
Title: How Do I Know if My Ulcerative Colitis Is Flaring?Category: Diseases and ConditionsCreated: 11/23/2021 12:00:00 AMLast Editorial Review: 11/23/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 23, 2021 Category: Nutrition Source Type: news

Can Ulcerative Colitis Be Healed?
Title: Can Ulcerative Colitis Be Healed?Category: Diseases and ConditionsCreated: 11/22/2021 12:00:00 AMLast Editorial Review: 11/22/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 22, 2021 Category: Nutrition Source Type: news

Prior Biologic Exposure No Barrier for Ozanimod in Colitis Prior Biologic Exposure No Barrier for Ozanimod in Colitis
Ozanimod is significantly more effective than placebo for treating patients with moderate to severe ulcerative colitis, regardless of prior biologic exposure, based on results of a phase 3 trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Patient Risk Key to Timing Biologics in IBD Patient Risk Key to Timing Biologics in IBD
The risk for complications and disease progression should be the main factors in the decision to initiate biologics for patients with Crohn's disease and ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 18, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Assisted Reproductive Therapy Safe in Women With IBD, but Efficacy Mixed Assisted Reproductive Therapy Safe in Women With IBD, but Efficacy Mixed
Assisted reproductive therapy is safe in women with inflammatory bowel disease, with outcomes likely similar in women with ulcerative colitis and medically managed Crohn's disease compared with the general population, suggest results of a systematic review and meta-analysis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 10, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab
In a statistical comparison, ozanimod matched vedolizumab and beat adalimumab for ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 2, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Upadacitinib Shows Potential for Ulcerative Colitis Upadacitinib Shows Potential for Ulcerative Colitis
Good efficacy and safety data provide hope for upadacitinib as an alternative JAK inhibitor for ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 26, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ustekinumab Maintenance Therapy in Ulcerative Colitis Ustekinumab Maintenance Therapy in Ulcerative Colitis
This study to assess the real-world effectiveness and safety of ustekinumab in patients with refractory ulcerative colitis confirms long-term effectiveness with a good safety profile.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Rectal Compliance Lower Than Normal in Ulcerative Colitis, but Recovery Is Possible Rectal Compliance Lower Than Normal in Ulcerative Colitis, but Recovery Is Possible
Rectal compliance is lower in patients with ulcerative colitis than in those without, but recovery is possible, researchers suggest.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 8, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How to Maintain Your Social Life When You Have IBD
About two years ago, as Samantha Plevney was dealing with a major Crohn’s disease flare-up, she decided to tell her gastroenterologist how it was affecting her emotional health. “I told him that I’m alive but I’m not living,” she recalls. “Not being able to see my friends because of the uncertainty of my health situation was making me feel worse. I think people with IBD, and their doctors, tend to focus on physical symptoms, and for good reason. But the mental-health effect that comes from social support is huge.” Inflammatory bowel disease (IBD) encompasses two conditions—Cr...
Source: TIME: Health - October 5, 2021 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Benefit of 5ASA Use After Anti-TNF or Immunomodulator in IBD Benefit of 5ASA Use After Anti-TNF or Immunomodulator in IBD
5ASA is still used as first-line therapy in the treatment of mild to moderate ulcerative colitis. Is there a benefit to continuing it once biological or immunomodulator therapy is initiated?Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

Do you suffer with IBS? Your symptoms could be a sign of a more serious condition - expert
IRRITABLE bowel syndrome causes abdominal symptoms that include constipation, diarrhoea, or both. However, the condition does not damage a person's bowel like ulcerative colitis or Crohn's disease can. Symptoms can consist of flare ups that can cause excruciating pain and can make going about your daily life uncomfortable. For years, IBS has often been diagnosed before another, more serious condition. (Source: Daily Express - Health)
Source: Daily Express - Health - September 25, 2021 Category: Consumer Health News Source Type: news

Can Cannabis Help Your Gut?
When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - September 23, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Source Type: news

Statins can lower cholesterol - but a study has found another surprising health benefit
STATINS are a group of medicines that can help lower the level of cholesterol in the blood. Satins can also be taken to prevent heart disease, including heart attacks and strokes. Now, a new study has found that the cheap pills may also help treat ulcerative colitis. (Source: Daily Express - Health)
Source: Daily Express - Health - September 18, 2021 Category: Consumer Health News Source Type: news

Statin Cholesterol Drugs May Help Fight Ulcerative Colitis
Title: Statin Cholesterol Drugs May Help Fight Ulcerative ColitisCategory: Health NewsCreated: 9/16/2021 12:00:00 AMLast Editorial Review: 9/17/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 17, 2021 Category: Nutrition Source Type: news

Statins don't just lower cholesterol! Study finds cheap pills may also help treat ulcerative colitis
Stanford University researchers have found that atrorvastatin - sold under the name Lipitor for just 54p a pill - slashes the risk of being hospitalised with the painful condition by half. (Source: the Mail online | Health)
Source: the Mail online | Health - September 16, 2021 Category: Consumer Health News Source Type: news

Statins may be an effective treatment for ulcerative colitis, study finds
Statins, the cholesterol-lowering drugs, may also help treat the symptoms of ulcerative colitis, a study published by the Journal of the American Medical Informatics Association found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 16, 2021 Category: Consumer Health News Source Type: news

Fecal Transplants: a New Treatment for IBD
Linda Ann Sasser has had ulcerative colitis since she was 20, but it wasn’t until May 2019, about 30 years later, that her condition hit a low point: not only did she have a major flare-up of chronic inflammatory bowel disease (IBD), but on top of it, she had Clostridioides difficile (or C. diff), a highly contagious bacterial infection that causes severe diarrhea and inflammation of the colon. “I became really, really sick with bloody diarrhea 30 times a day and chronic stomach pain,” Sasser says. While hospitalized for 12 days, she was given oral steroid medications, which didn’t help, then IV ste...
Source: TIME: Health - September 9, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Disease feature Source Type: news

VARSITY: Better Outcomes With Vedolizumab Than Adalimumab in UC VARSITY: Better Outcomes With Vedolizumab Than Adalimumab in UC
In patients with moderate to severe ulcerative colitis, treatment with vedolizumab leads to better histologic outcomes than treatment with adalimumab, according to findings from the VARSITY trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 3, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Ultrasound Detects Ulcerative Colitis Disease Activity
FRIDAY, Aug. 27, 2021 -- A new ulcerative colitis intestinal ultrasound (UC-IUS) index shows strong correlation with endoscopy for detection of disease activity, according to a study published in the August issue of the Journal of Crohn's and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 27, 2021 Category: Pharmaceuticals Source Type: news

InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
STOCKHOLM, Aug. 24, 2021 -- (Healthcare Sales & Marketing Network) -- InDex Pharmaceuticals Holding AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to start the phase III clinical study CONCLUDE in the United... Biopharmaceuticals, Gastroenterology, FDA InDex Pharmaceuticals, cobitolimod, ulcerative colitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 24, 2021 Category: Pharmaceuticals Source Type: news

Persistence With Biologics in Inflammatory Bowel Diseases Persistence With Biologics in Inflammatory Bowel Diseases
This study aimed to analyze persistence of biological agents in Crohn's disease and ulcerative colitis. What factors might influence treatment persistence?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 18, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Ulcerative colitis: Three gastrointestinal symptoms indicating risk - medicines to avoid
ULCERATIVE colitis is an inflammatory condition which can cause painful flare-ups and symptoms. How can you know if you may be suffering with the condition and, if so, what medication is best to avoid to reduce prolonging pain? (Source: Daily Express - Health)
Source: Daily Express - Health - August 17, 2021 Category: Consumer Health News Source Type: news

Tofacitinib As Salvage Therapy for Refractory Severe UC Tofacitinib As Salvage Therapy for Refractory Severe UC
In a cohort of patients hospitalized with a severe flare of ulcerative colitis, rescue therapy with tofacitinib avoided colectomy in a substantial proportion of cases.Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 11, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

Is Pancolitis the Same as Ulcerative Colitis?
Title: Is Pancolitis the Same as Ulcerative Colitis?Category: Diseases and ConditionsCreated: 8/3/2021 12:00:00 AMLast Editorial Review: 8/3/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 3, 2021 Category: Nutrition Source Type: news

How Do You Get Diagnosed with Ulcerative Colitis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 28, 2021 Category: General Medicine Source Type: news

VTE Risk Up for Children With Inflammatory Bowel Disease
Venous thromboembolism occurred less often for those with Crohn disease versus ulcerative colitis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 27, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Pediatrics, Pharmacy, Journal, Source Type: news

How Do You Diagnose Ulcerative Colitis?
Title: How Do You Diagnose Ulcerative Colitis?Category: Diseases and ConditionsCreated: 7/23/2021 12:00:00 AMLast Editorial Review: 7/23/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - July 23, 2021 Category: Nutrition Source Type: news

Cambridge microbiome startup's shares sliced in half after key trial failure
Microbiome startup Seres Therapeutics' shares are in a free fall after the company announced that its ulcerative colitis drug had failed in a mid-stage clinical trial. Seres (Nasdaq: MCRB) had been developing the drug in partnership with Nestlé Health Science as part of its suite of bacteria-based drugs, several of which are in clinical development. The ulcerative colitis study will be shut down, as the drug resulted in "no meaningful clinical differences" in a placebo comparison trial involving… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 22, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Adalimumab Safe and Effective in Children With Ulcerative Colitis Adalimumab Safe and Effective in Children With Ulcerative Colitis
Adalimumab is effective and well tolerated in children with moderate-to-severe ulcerative colitis, according to results of the ENVISION I study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2021 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Ustekinumab in Infliximab-refractory Pediatric UC Ustekinumab in Infliximab-refractory Pediatric UC
This study evaluated the efficacy of ustekinumab following failure of prior biologics in pediatric ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Crohn ’s Disease vs Ulcerative Colitis Difference
Crohn ’s Disease vs. Ulcerative Colitis: What's the Difference? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 21, 2021 Category: General Medicine Source Type: news

What Is Life Expectancy with Ulcerative Colitis
What Is the Life Expectancy with Ulcerative Colitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 18, 2021 Category: General Medicine Source Type: news

What Is the Best Treatment for Ulcerative Colitis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 18, 2021 Category: General Medicine Source Type: news

What Were First Symptoms of Ulcerative Colitis
What Were Your First Symptoms of Ulcerative Colitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 17, 2021 Category: General Medicine Source Type: news

What Is the Life Expectancy of Ulcerative Colitis
What Is the Life Expectancy of Someone with Ulcerative Colitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 17, 2021 Category: General Medicine Source Type: news

COVID Vaccines Appear Safe for People With IBD
THURSDAY, June 10, 2021 -- The Pfizer and Moderna COVID-19 vaccines appear to be safe for people with inflammatory bowel diseases (IBD), a new study finds. IBDs -- which includes Crohn's disease and ulcerative colitis -- are chronic conditions... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 10, 2021 Category: General Medicine Source Type: news

FDA Approves Ozanimod (Zeposia) for Ulcerative Colitis FDA Approves Ozanimod (Zeposia) for Ulcerative Colitis
Once-daily, oral ozanimod is the first sphingosine-1-phosphate receptor modulator approved for adults with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 28, 2021 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news

'Good' bacteria show promise for clinical treatment of Crohn's disease, ulcerative colitis
(University of North Carolina Health Care) Balfour Sartor, MD, Midget Distinguished Professor of Medicine, Microbiology and Immunology, is the senior author of a study that shows how a novel consortium of bacteria that live in the digestive tracts of healthy individuals can be used to prevent and treat aggressive colitis in humanized mouse models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2021 Category: International Medicine & Public Health Source Type: news